Abstract
Background: Since 2010, the results of ToGA trial showed that Trastuzumab plus cisplatin-based chemotherapy (CHT) should be the new standard therapy for patients (pts) with HER2-positive (HER2+) advanced gastric cancer, improving overall survival (OS) and progression-free survival (PFS). Nonetheless, there is still scarce evidence regarding the role of HER2 status in pts with locally advanced resectable gastric cancer (LARGC). Our aim was to assess if HER2+ in LARGC could be a prognostic factor correlated to a poor survival outcome and a predictive factor of response to standard perioperative CHT in our area.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
